New Trade for July 19th, 2022

One area of the market where stocks can be found to produce 10x, even 20x returns, regardless of what’s happening elsewhere, is biotech. Looking at the performance of the past ten years, if the biotechnology industry were a sector, it would be the best performing one. Over the past decade, biotech stocks have returned 524%. That beats every last sector, it beats the broader health care sector by 200 percentage points, and it’s nearly double the S&P 500’s total return in that same time frame.  

Specifically, genomics is one niche within the biotech group that could offer unimaginable returns. Still, the technology is so new and complex that many investors shy away from companies making astounding advancements.  

There’s clearly money to be made in the discovery of new treatments for anything from the flu to cancer. But genomics stocks carry substantial risk. While positive data from a trial could send their stocks soaring, a setback or failure can crush their returns, making them difficult buy-and-hold investments.  

Today we’re highlighting a rare, buy-and-hold genomics investment that provides ground floor access to the innovators of tomorrow, along with their potential nose-bleed returns, while minimizing risk.

Stansberry Research:

Wall Street Legend Warns: “A Strange Day Is Coming to America”

“A massive and surprising new transition could determine the next group of millionaires,” says Chaikin, who predicted the 2020 market crash. “While leaving 99% of the public worse off than before.”

“If you own regular stocks, you’re in for a big surprise,” he adds. [Full Story Here…]

One solution for anyone who wants to benefit from genomics advancements but lacks the expertise needed to evaluate individual companies from the group confidently is to delegate individual stock picking to the professionals. In today’s trade, we’ll focus on an exchange-traded fund (ETF) that provides an opportunity for investors seeking access to companies at the forefront of genomics innovation. 

iShares Genomics Immunology and Healthcare ETF (IDNA) holds a concentrated portfolio of global companies in the biopharmaceutical and healthcare equipment and services industries that could benefit from the long-term growth and innovation in genomics immunology and bioengineering. The fund is passively managed, and holdings are weighted by market cap and are constrained such that no individual security exceeds the 4% weight of the portfolio. The index rebalances semi-annually.

It’s worth noting that IDNA beat Cathie Woods’ ARK Genomic Revolution ETF (ARKG) in the first ten weeks of 2020 when global markets were rocked by the coronavirus outbreak and investors were eagerly hunting for potential profit in companies researching treatment and vaccines. 

iShares Genomics Immunology and Healthcare ETF (IDNA)

• Weighted Average Market Cap  $42.71B
• Price / Book Ratio  2.46
• YTD Return  – 29%
• Yield  0.88%
• Expense Ratio  0.47%
• Net Assets   188.04M
• Number of Holdings  50

Empire Research:

A company with 400 million ‘patents’

One company has quietly compiled more than 400 million official trade secrets.

Trade secrets are like patents in that they protect valuable and proprietary information…

But unlike patents, trade secrets take less time to register… and more importantly, they never expire.

Which is a huge advantage for this little-known company.

You see, this company is using these trade secrets to build the world’s largest “codebase,” which will bethe key to it becoming “America’s Next Big Monopoly.”

Not surprisingly, Wall Street is starting to take notice. And the smart money is already pouring in.

Tech investor Cathie Wood has invested over $80 million already, and Microsoft founder Bill Gates has invested as well.

Get the details here before this story hits the mainstream media.